) We are proposing to have a central animal CORE for breeding the transgenic mice. All mice required by the four investigators on this program project would be provided by the CORE. Dr. Jaffee would be the CORE leader since she has been breeding the colony and has been successful. The CORE would be responsible for breeding and distributing the mice. Individual investigators will be responsible for housing mice that are used in experiments. There are four specific aims of this CORE: 1) Breeding the transgenic mice to the numbers required for studies proposed in all four projects; 2) Mating female mice once between the age of 12 and 14 weeks to enhance expression of HER-2/neu which in turn will enhance the rate of spontaneous tumor development; 3) Quarterly testing of 5-10 mice in the colony for expression of the HER-2/neu transgenic; 4) Distribution of mice to all four investigators. This CORE is essential for the conduction of the in vivo experiments proposed by all four project leaders.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19CA072108-06
Application #
6455096
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-05-17
Project End
2002-04-30
Budget Start
Budget End
Support Year
6
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Disis, Mary L; Bernhard, Helga; Jaffee, Elizabeth M (2009) Use of tumour-responsive T cells as cancer treatment. Lancet 373:673-83
Emens, Leisha A (2008) Chemotherapy and tumor immunity: an unexpected collaboration. Front Biosci 13:249-57
Manning, Elizabeth A; Ullman, John G M; Leatherman, James M et al. (2007) A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 13:3951-9
Prendergast, George C; Jaffee, Elizabeth M (2007) Cancer immunologists and cancer biologists: why we didn't talk then but need to now. Cancer Res 67:3500-4
Emens, L A; Reilly, R T; Jaffee, E M (2005) Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocr Relat Cancer 12:1-17
Ercolini, Anne M; Ladle, Brian H; Manning, Elizabeth A et al. (2005) Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201:1591-602
Laheru, Dan A; Pardoll, Drew M; Jaffee, Elizabeth M (2005) Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology. Mol Cancer Ther 4:1645-52
Emens, Leisha A; Jaffee, Elizabeth M (2005) Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 65:8059-64
Emens, Leisha A; Reilly, R Todd; Jaffee, Elizabeth M (2004) Augmenting the potency of breast cancer vaccines: combined modality immunotherapy. Breast Dis 20:13-24
Hung, Chien-Fu; Cheng, Wen-Fang; He, Liangmei et al. (2003) Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res 63:2393-8

Showing the most recent 10 out of 32 publications